Traws Pharma Reports Positive Interim Results for Ratutrelvir in Paxlovid-Ineligible COVID-19 Patients

Reuters12-17

<a href="https://laohu8.com/S/TRAW">Traws Pharma</a> Reports Positive Interim Results for Ratutrelvir in Paxlovid-Ineligible COVID-19 Patients

Traws Pharma Inc. has announced interim data from an ongoing randomized, open-label Phase 2 clinical study of ratutrelvir, an investigational oral, ritonavir-free Mpro/3CL protease inhibitor, in patients with mild-to-moderate COVID-19. The interim analysis demonstrated a differentiated clinical profile for ratutrelvir compared to PAXLOVID™, with fewer adverse events and no viral rebounds. The data also indicated activity in patients who are ineligible for Paxlovid, addressing a population with limited treatment options. The final data analysis from the study is expected to be reported in January 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Traws Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9603482-en) on December 17, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2592399184?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-17 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592399184","market":"fut","top_or_hot":-1,"title":"Traws Pharma Reports Positive Interim Results for Ratutrelvir in Paxlovid-Ineligible COVID-19 Patients","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/TRAW\">Traws Pharma</a> Reports Positive Interim Results for Ratutrelvir in Paxlovid-Ineligible COVID-19 Patients\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Traws Pharma Inc. has announced interim data from an ongoing randomized, open-label Phase 2 clinical study of ratutrelvir, an investigational oral, ritonavir-free Mpro/3CL protease inhibitor, in patients with mild-to-moderate COVID-19. The interim analysis demonstrated a differentiated clinical profile for ratutrelvir compared to PAXLOVID™, with fewer adverse events and no viral rebounds. The data also indicated activity in patients who are ineligible for Paxlovid, addressing a population with limited treatment options. The final data analysis from the study is expected to be reported in January 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Traws Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9603482-en) on December 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Traws Pharma Reports Positive Interim Results for Ratutrelvir in Paxlovid-Ineligible COVID-19 Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTraws Pharma Reports Positive Interim Results for Ratutrelvir in Paxlovid-Ineligible COVID-19 Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-17 19:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/TRAW\">Traws Pharma</a> Reports Positive Interim Results for Ratutrelvir in Paxlovid-Ineligible COVID-19 Patients\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Traws Pharma Inc. has announced interim data from an ongoing randomized, open-label Phase 2 clinical study of ratutrelvir, an investigational oral, ritonavir-free Mpro/3CL protease inhibitor, in patients with mild-to-moderate COVID-19. The interim analysis demonstrated a differentiated clinical profile for ratutrelvir compared to PAXLOVID™, with fewer adverse events and no viral rebounds. The data also indicated activity in patients who are ineligible for Paxlovid, addressing a population with limited treatment options. The final data analysis from the study is expected to be reported in January 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Traws Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9603482-en) on December 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999014005.SGD","symbol_name":"United Global Durable Equities Fund Acc SGD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDL38GghF:1","article_id":"2592399184","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2592399184","pubTimestamp":1765969221,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Traws Pharma Inc. has announced interim data from an ongoing randomized, open-label Phase 2 clinical study of ratutrelvir, an investigational oral, ritonavir-free Mpro/3CL protease inhibitor, in patients with mild-to-moderate COVID-19. The interim analysis demonstrated a differentiated clinical profile for ratutrelvir compared to PAXLOVID, with fewer adverse events and no viral rebounds. The data also indicated activity in patients who are ineligible for Paxlovid, addressing a population with limited treatment options. The final data analysis from the study is expected to be reported in January 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Traws Pharma Inc. published the original content used to generate this news brief via Glob","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","TRAW":"TRAWS PHARMA","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4007":"制药","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","NDAQ":"纳斯达克OMX交易所","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4112":"金融交易所和数据"},"translate_title":"Traws Pharma报告Ratutrelvir在不符合Paxlovid条件的COVID-19患者中的积极中期结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TRAW":0.9,"NDAQ":0.9},"content_text":"Traws Pharma Reports Positive Interim Results for Ratutrelvir in Paxlovid-Ineligible COVID-19 Patients\n    \n\n        Traws Pharma Inc. has announced interim data from an ongoing randomized, open-label Phase 2 clinical study of ratutrelvir, an investigational oral, ritonavir-free Mpro/3CL protease inhibitor, in patients with mild-to-moderate COVID-19. The interim analysis demonstrated a differentiated clinical profile for ratutrelvir compared to PAXLOVID™, with fewer adverse events and no viral rebounds. The data also indicated activity in patients who are ineligible for Paxlovid, addressing a population with limited treatment options. The final data analysis from the study is expected to be reported in January 2026.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Traws Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9603482-en) on December 17, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2592399184","isCrawlerRequest":true}